Atherosclerosis and its complications such as myocardial infarction and stroke are the leading cause of morbidity and mortality in the U.S., and account for nearly 75% of all deaths from cardiovascular disease (CVD). In addition, chronic kidney disease (CKD) is a common disease affecting as high as 10% of the world's population. CKD causes hyperuremia which are known as severe precondition exacerbating atherosclerosis. Therefore, novel therapies are urgently needed to inhibit the acceleration of atherosclerosis associated with CKD. However, the mechanisms underlying how CKD accelerates atherosclerosis remain poorly defined. We recently reported that caspase-1 (Casp1) activation plays an essential role in sensing metabolic danger signals and initiates inflammation, a condition determines the initiation and progression of atherosclerosis. However, the role of Casp1 signaling in CKD-accelerated atherosclerosis has not been studied. Our preliminary study suggest that Casp1 activation may contribute to CKD-accelerated atherosclerosis. The central hypothesis to be examined in this proposal is that Casp1 activation mediates vessel wall atherogenic cellular pathology in CKD patients and CKD mice, and that Casp1 suppression could rescue CKD-related atherosclerosis. We will examine the effect of CKD on endothelial cell (EC) activation (Yang), inflammatory monocyte (MC) differentiation (Wang), and vascular smooth muscle cell (VSMC) migration/proliferation (Choi) and dissect the underlying mechanism. We will test our hypothesis by using the following three aims:
Aim 1 will examine Casp1 activation in EC, MC, and VSMC in CKD- CVD patients, and CKD-atherosclerosis mice (phenotypic studies).
Aim 2 will examine the mechanisms underlying CKD-induced Casp1 activation and vessel wall cell pathological changes (mechanistic studies).
Aim 3 will determine the causative roles of Casp1-NLRP3 inflammasome on vessel wall cell pathological changes and in mouse CKD-atherosclerosis (therapy/verification studies). Success of this project will lead to the development of novel therapeutics for CKD-related CVD.

Public Health Relevance

Chronic kidney disease (CKD) is a common disease affecting >15% of the US adult population and has cardiovascular mortality10- to 30-folds greater than that in general population. We will examine the contribution and mechanism of caspase-1- inflammasome pathway in CKD-accelerated vascular disease. Success of this study would characterize caspase-1 inflammasome molecular signaling in CKD-accelerated atherosclerosis and lead to the development of new therapeutics for the treatment of CKD-related CVD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL131460-02
Application #
9198259
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Fleg, Jerome
Project Start
2016-01-01
Project End
2019-12-31
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Wang, Luqiao; Nanayakkara, Gayani; Yang, Qian et al. (2017) A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis-associated molecular pattern receptors. J Hematol Oncol 10:168
Li, Xinyuan; Fang, Pu; Yang, William Y et al. (2017) Mitochondrial ROS, uncoupled from ATP synthesis, determine endothelial activation for both physiological recruitment of patrolling cells and pathological recruitment of inflammatory cells. Can J Physiol Pharmacol 95:247-252
Lakhter, Vladimir; Zack, Chad J; Brailovsky, Yevgeniy et al. (2017) Sex differences in utilization and outcomes of catheter-directed thrombolysis in patients with proximal lower extremity deep venous thrombosis - Insights from the Nationwide Inpatient Sample. Vasc Med 22:128-134
Greenberg, Jacques; Jayarajan, Senthil; Reddy, Sridhar et al. (2017) Long-Term Outcomes of Fistula First Initiative in an Urban University Hospital-Is It Still Relevant? Vasc Endovascular Surg 51:125-130
Dai, Jin; Fang, Pu; Saredy, Jason et al. (2017) Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation. J Hematol Oncol 10:141
Shao, Ying; Nanayakkara, Gayani; Cheng, Jiali et al. (2017) Lysophospholipids and Their Receptors Serve as Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury. Antioxid Redox Signal :
Cheng, Jiali; Nanayakkara, Gayani; Shao, Ying et al. (2017) Mitochondrial Proton Leak Plays a Critical Role in Pathogenesis of Cardiovascular Diseases. Adv Exp Med Biol 982:359-370
Xu, Yanjie; Xia, Jixiang; Liu, Suxuan et al. (2017) Endocytosis and membrane receptor internalization: implication of F-BAR protein Carom. Front Biosci (Landmark Ed) 22:1439-1457
Shao, Ying; Chernaya, Valeria; Johnson, Candice et al. (2016) Metabolic Diseases Downregulate the Majority of Histone Modification Enzymes, Making a Few Upregulated Enzymes Novel Therapeutic Targets--""Sand Out and Gold Stays"". J Cardiovasc Transl Res 9:49-66
Xi, Hang; Zhang, Yuling; Xu, Yanjie et al. (2016) Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells. Circ Res 118:1525-39

Showing the most recent 10 out of 15 publications